Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 153-160

  Keedy, Vicki L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

mTOR; Ridaforolimus; Sarcoma

Indexed keywords

EVEROLIMUS; M 8669; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PROTEIN BINDING; FATIGUE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; LUNG DISEASE; LUNG EMBOLISM; LYMPHOMA; MANTLE CELL LYMPHOMA; METASTASIS; NAUSEA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PLEURA EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; THYMOMA;

EID: 84873893872     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S19055     Document Type: Review

References (83)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Darling J. A different view of sarcoma statistics. The Electronic Sarcoma Update Newsletter 2007. Available from: http://sarcomahelp.org/sarcoma_statistics.html. Accessed January 2011.
3. Van Glabbeke M, van Oosterom AT, Oosterhis J W, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing firstline regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17(1):150-157.
4. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol. 1975;1(1):63-76.
5. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982;50(12): 2757-2762.
6. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in frst-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13(7):1537-1545.
7. Antman K, Crowley J, Balcerzak S P, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276-1285.
8. Le Cesne A, Judson I, Crowther D, et al. Randomized Phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18(14):2676-2684.
9. Worden F P, Taylor JM, Biermann JS, et al. Randomized phase II evaluation of 6 mg/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005;23(1):105-112.
10. Bramwell VH, Anderson D, Charette ML; The Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003;(3):CD003293.
11. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755-2763.
12. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701.
13. Antman K, Crowley J, Balcerzak S P, et al. A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer. 1998;82(7):1288-1295.
14. Bramwell VH, Burgers M V, Souhami RL, et al. A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: A Study of the European Osteosarcoma Intergroup. Sarcoma. 1997;1(3-4):155-160.
15. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99(2):112-128.
16. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47(6):795-800.
17. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559-568.
18. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721-726.
19. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann N Y Acad Sci. 1993;685:73-85.
20. Almond PS, Moss A, Nakhleh R, et al. Rapamycin in a porcine renal transplant model. Ann N Y Acad Sci. 1993;685:121-122.
21. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270(2):815-822.
22. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022): 905-909.
23. Zheng XF, Fiorentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-130.
24. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73(3): 585-596.
25. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144(1): 251-258.
26. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1995;58(5):373-395.
27. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2): 177-189.
28. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18(23):2893-2904.
29. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91-99.
30. Vander Haar E, Lee SI, Bandhakavi S, Griffn TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9(3):316-323.
31. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648-657.
32. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans. 2003;31(Pt 3):573-578.
33. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: flling the GAP in the mTOR signaling pathway. Trends Biochem Sci. 2004;29(1):32-38.
34. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151-3171.
35. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10(3):457-468.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098-1101.
37. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28(12):4104-4115.
38. Tato I, Bartrons R, Ventura F, Rosa JL. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem. 2011;286(8):6128-6142.
39. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell. 2011;144(5):757-768.
40. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307-318.
41. Sabine VS, Sims AH, Macaskill EJ, et al. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010;122(2):419-428.
42. Neufeld T P. TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol. 2010;22(2):157-168.
43. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27(14):1919-1931.
44. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specifcity. Cell. 2006;127(1):125-137.
45. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defnes a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14): 1296-1302.
46. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against ageand diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431(7005):200-205.
47. Russell RC, Fang C, Guan KL. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development. 2011; 138(16):3343-3356.
48. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29-86.
49. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37(1):19-24.
50. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563-1568.
51. Krymskaya V P, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol. 2003;28(5): 546-550.
52. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-1947.
53. Makowski L, Hayes DN. Role of LKB1 in lung cancer development. Br J Cancer. 2008;99(5):683-688.
54. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11(4):289-301.
55. Eng C P, Sehgal SN, Vézina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo). 1984;37(10):1231-1237.
56. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60(3):264-270.
57. Withers DJ, Seufferlein T, Mann D, Garcia B, Jones N, Rozengurt E. Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells. J Biol Chem. 1997; 272(4):2509-2514.
58. Oh CD, Kim SJ, Ju J W, et al. Immunosuppressant rapamycin inhibits protein kinase C alpha and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis. Eur J Pharmacol. 2001;427(3): 175-185.
59. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53(11):2748-2756.
60. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci. 2003;33(2):131-141.
61. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59(4): 886-894.
62. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS//FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene. 2003;22(58): 9282-9287.
63. Lipskar AM, Glick RD, Huang J, et al. Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg. 2009;44(6):1139-1146; discussion 1146-1147.
64. Hu J, Rao UN, Jasani S, Khanna V, Yaw K, Surti U. Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. Cancer Genet Cytogenet. 2005;161(1):20-27.
65. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13(6):748-753.
66. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008;20(4):419-427.
67. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272(49):30822-30827.
68. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65(24):11459-11468.
69. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene. 2006;25(7):1042-1052.
70. Chen J, Zheng X F, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12rapamycin-associated protein and characterization of a critical serine residue. Proc Nat Acad Sci U S A. 1995;92(11):4947-4951.
71. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/mice. Proc Natl Acad Sci U S A. 2001;98(18):10320-10325.
72. Porcher R, Kerob D, Dupin N, et al. Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi's sarcoma (C06-46). J Clin Oncol. 2011;29:1067.
73. Richter S, Pink D, Hohenberger P, et al. Multicenter, triple-arm, singlestage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. J Clin Oncol. 2010;28(15s):10038.
74. Ridaforolimus. Drugs R D. 2010;10(3):165-178.
75. Hartford CM, Desai AA, Janisch L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009;15(4): 1428-1434.
76. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26(3):361-367.
77. Chawla S P, Staddon A P, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78-84.
78. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67(13):6325-6332.
79. Wendel HG, Lowe S W. Reversing drug resistance in vivo. Cell Cycle. 2004;3(7):847-849.
80. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011; 17(4):871-879.
81. Naing A, LoRusso P, Fu S, et al. Cixutumumab combined with temsirolimus in patients with refractory Ewing's sarcoma. J Clin Oncol. 2011;29:10031.
82. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868-880.
83. Fletcher CDM, Unni KK, Mertens F, editors. World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.